United Therapeutics (NASDAQ:UTHR) CEO Sells $4,987,405.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction on Friday, March 20th. The shares were sold at an average price of $524.99, for a total value of $4,987,405.00. Following the completion of the sale, the chief executive officer owned 40,513 shares of the company’s stock, valued at approximately $21,268,919.87. This represents a 19.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

United Therapeutics Price Performance

NASDAQ:UTHR opened at $541.60 on Thursday. The business’s 50-day moving average is $493.58 and its two-hundred day moving average is $471.33. The firm has a market capitalization of $23.74 billion, a PE ratio of 19.41, a price-to-earnings-growth ratio of 1.92 and a beta of 0.84. United Therapeutics Corporation has a 12 month low of $266.98 and a 12 month high of $549.50.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, topping the consensus estimate of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The company had revenue of $790.20 million during the quarter, compared to the consensus estimate of $814.80 million. The company’s revenue was up 7.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $6.19 earnings per share. Equities analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current year.

Analyst Upgrades and Downgrades

UTHR has been the topic of a number of analyst reports. HC Wainwright lifted their price objective on shares of United Therapeutics from $525.00 to $600.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. Cantor Fitzgerald upped their target price on shares of United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research note on Thursday, March 12th. Oppenheimer raised their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a report on Thursday, February 26th. Bank of America reaffirmed a “neutral” rating on shares of United Therapeutics in a research note on Wednesday, February 25th. Finally, TD Cowen boosted their price objective on shares of United Therapeutics from $525.00 to $575.00 and gave the stock a “buy” rating in a report on Wednesday, February 25th. Nine equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, United Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $549.91.

United Therapeutics News Roundup

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Several brokerages have lifted price targets and reiterated buy/outperform views (examples cited include HC Wainwright, RBC, Cantor Fitzgerald and UBS), supporting upside expectations and helping sentiment. Analyst Coverage Summary
• Positive Sentiment: Wells Fargo published a bullish forecast for UTHR, calling for meaningful price appreciation and adding directional support to the tape. Wells Fargo Research
• Positive Sentiment: Recent quarterly results showed EPS outperformance versus consensus (EPS beat), underpinning the fundamental case even as revenue slightly missed; analysts’ upward revisions follow those results. Quarterly Results Summary
• Neutral Sentiment: Brokerage consensus remains a “Moderate Buy” — constructive but not unanimous; this keeps expectations elevated but measured. Analyst Consensus
• Neutral Sentiment: Institutional ownership is high and several funds reported increasing stakes in recent quarters, which can support liquidity and reduce volatility. Institutional Holdings
• Negative Sentiment: Insider selling: CEO Martine Rothblatt sold 9,500 shares (~$5.0M) and CFO James Edgemond sold 10,000 shares (~$5.27M) in March; large officer sales can pressure sentiment even if company says sales are routine. SEC filings: CEO sale CEO SEC Filing, CFO sale CFO SEC Filing
• Neutral Sentiment: Short-interest reports in recent feeds show data anomalies (zero reported shares / NaN changes) and are not providing a clear short-squeeze or bearish signal at this time. Short Interest Data

Hedge Funds Weigh In On United Therapeutics

A number of institutional investors have recently made changes to their positions in the business. Clearstead Advisors LLC grew its position in shares of United Therapeutics by 8.9% during the third quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company’s stock worth $117,000 after buying an additional 23 shares in the last quarter. Independent Advisor Alliance raised its holdings in United Therapeutics by 3.3% in the fourth quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company’s stock valued at $406,000 after acquiring an additional 27 shares in the last quarter. Bessemer Group Inc. boosted its stake in United Therapeutics by 2.6% during the 3rd quarter. Bessemer Group Inc. now owns 1,126 shares of the biotechnology company’s stock valued at $472,000 after acquiring an additional 28 shares during the last quarter. Florida Financial Advisors LLC boosted its stake in United Therapeutics by 5.4% during the 4th quarter. Florida Financial Advisors LLC now owns 550 shares of the biotechnology company’s stock valued at $268,000 after acquiring an additional 28 shares during the last quarter. Finally, NDVR Inc. grew its holdings in United Therapeutics by 5.1% during the 4th quarter. NDVR Inc. now owns 616 shares of the biotechnology company’s stock worth $300,000 after acquiring an additional 30 shares in the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.